A review of pharmaceutical scheduling processes in six countries and the effect on consumer access to medicines

International Journal of Pharmacy Practice

Volumn 14, Issue 2, 2006, Pages 95-104

  Gilbert, Andrew ^a   Rao, Deepa ^a   Quintrell, Neil ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ADRENALIN; ANTIBIOTIC AGENT; BUPRENORPHINE; CETIRIZINE; CLOTRIMAZOLE; DEXTROMETHORPHAN; DICLOFENAC; ECONAZOLE; FAMOTIDINE; GLYCERYL TRINITRATE; INSULIN; KETOPROFEN; KETOTIFEN; NICOTINE; NYSTATIN; PROCHLORPERAZINE; PYROVALERONE; SCOPOLAMINE; TERBINAFINE; TIOCONAZOLE;

AUSTRALIA; CANADA; CONSUMER; DRUG CLASSIFICATION; DRUG PACKAGING; DRUG SURVEILLANCE PROGRAM; FRANCE; HEALTH CARE ACCESS; INTERMETHOD COMPARISON; NEW ZEALAND; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SELF MEDICATION; UNITED KINGDOM; UNITED STATES;

EID: 33744500743     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/ijpp.14.2.0003     Document Type: Review

References (50)

1. Spivey RN, Wertheimer AI, Rucker TD. International pharmaceutical services, the drug industry and pharmacy practice in twenty-three major countries of the World. Binghamton: Pharmaceutical Products Press; 1996.
2. Commonwealth Department of Health and Ageing. National medicines policy, www.nmp.health.gov.au/ (accessed February 1, 2006).
3. Commonwealth Department of Health and Ageing. Quality use of medicines. www.nmp.health. gov.au/quality.htm (accessed February 1, 2006).
4. Moore B, editor. The Australian Oxford dictionary, 2nd ed. South Melbourne: Oxford University Press; 2004.
5. Lowe NK, Ryan-Wenger NM. Over-the-counter medications and self-care. Nurse Pract 1999;24:34-42, 44.
6. Lipsky MS, Waters T. The 'prescription-to-OTC switch' movement - its effects on antifungal vaginitis preparations. Arch Fam Med 1999;8:297-300.
7. World Medical Association. Statement on self-medication, Washington: World Medical Association; 2002. www.wma. net/e/policy/s7.htm (accessed February 1, 2006).
8. Blenkinsopp A, Bradley C. Patients, society and the increase in self medication. BMJ 1996;312:629-32.
9. Blenkinsopp A, Bond C. Over the counter medication. London: British Medical Association; 2005.
10. Brass E. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345:810-16.
11. Soller RW. Evolution of self-care with over-the-counter medications. Clin Ther 1998;20(suppl. C):C134-40.
12. Bradley C, Blenkinsopp A. Over the counter drugs. The future for self medication. BMJ 1996;312:835-7.
13. Bond C, Bradley C. The interface between the community pharmacist and patients. BMJ 1996;312:758-60.
14. Thomas DH, Noyce PR. The interface between self-medication and the NHS. BMJ 1996;312:688-91.
15. Paulose-Ram R, Hirsch R, Dillon C et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315-26.
16. Kline and Company. Rx to OTC switch survey: data on file. Washington DC: Non-prescription Drug Manufacturers' Association; 1994.
17. Gallup Organisation Survey. Rx to OTC switch. Alexandria, Virginia: National Association of Chain Drug Stores; 1990.
18. Payne K, Ryan-Woolley BM, Noyce PR. Role of consumer attributes in predicting the impact of medicines deregulation on National Health Service prescribing in the United Kingdom. Int J Pharm Pract 1998;6:150-8.
19. Andersson F, Hatziandreu E. The costs and benefits of switching a drug from prescription only to over the counter status. PharmacoEconomics 1992;2:388-96.
20. Rizzo JA, Ozminkowski RJ, Goetzel RZ. Prescription to over-the-counter switching of drugs. Dis Manag Health Outcomes 2005;13:83-92.
21. 2 blockers. Med Care 1990;28:834-52.
22. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care 2005;11:374-82.
23. Keeler TE, Hu TW, Keith A et al. The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ 2002;11:389-402.
24. Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales. Experiences from Sweden 1980-1994. J Clin Pharm Ther 1996;21:423-30.
25. Bessell T, Hiller J, Sansom L, Willson K. Pharmacist only medicines: public health issues. Aust Pharm 2001;20:326-9.
26. The role of the pharmacist in self-care and self-medication: report of the 4th WHO Consultative Group on the Role of the Pharmacist. The Hague: World Health Organization; 1998.
27. Alexander C, Mohajir N, Meltzer DO. Consumers' perceptions about risk of and access to non-prescription medications. J Am Pharm Assoc 2005;45:363-70.
28. Bissell P, Ward PR, Noyce PR. Mapping the contours of risk: consumer perceptions of non-prescription medicines. J Soc Admin Pharm 2000;17:136-42.
29. Hassell K, Noyce PR, Rogers A, Harris J, Wilkinson J. A pathway to the GP: the pharmaceutical 'consultation' as the first port of call in primary health care. Fam Pract 1997;14:498-502.
30. Hassell K, Rogers A, Noyce PR. Community pharmacy as a primary health and self-care resource: a framework for understanding pharmacy utilization. Health Soc Care Community 2000;8:40-9.
31. Navigating the medication marketplace: how consumers choose. Washington DC: A Joint Survey from Prevention Magazine and the American Pharmaceutical Association; 1997.
32. Wazaify M, Shields E, Hughes CM, McElnay JC. Societal perspectives on over the counter (OTC) medicines. Fam Pract 2005;22:170-6.
33. Juhl RP. Prescription to over the counter switch: a regulatory perspective. Clin Ther 1998;20(suppl. C):C111-17.
34. Schulke DG. American Pharmaceutical Association review of literature on prescription to over the counter drug switches. Clin Ther 1998;20(suppl. C):C124-33.
35. Krishnan HS, Schaeffer M. Evaluation of the impact of pharmacists' advice giving on the outcomes of self-medication in patients suffering from dyspepsia. Pharm World Sci 2000;22:102-3.
36. Sinclair HK, Bond CM, Hannaford PC. Over-the-counter ibuprofen: how and why is it used? Int J Pharm Pract 2000;8:121-7.
37. 2 receptor antagonists to over-the-counter status in Finland - implications for consumption and adverse effects. Clin Drug Invest 2005;25:243-8.
38. Shiffman S, Rolf CN, Hellebusch SJ et al. Real world efficacy of prescription and over the counter nicotine replacement therapy. Addiction 2002;97:505-16.
39. World Self-medication Industry. Legal status of selected ingredients in the European Union, www.wsmi.org (accessed February 1, 2006).
40. Commonwealth Department of Health and Aged Care. Therapeutics goods administration, www.tga.gov.au/ndpsc/susdp.htm (accessed February 1, 2006).
41. National Association of Pharmacy Regulatory Authorities. The National Drug Scheduling Advisory Committee (NDSAC). www.napra.org/docs/0/92/115.asp (accessed February 1, 2006).
42. New Zealand Ministry of Health. New Zealand regulatory guidelines for medicines. Wellington; 2001. www.medsafe. govt.nz/reg.htm (accessed February 1, 2006).
43. Medicines and Healthcare products Regulatory Agency. Licensing of medicines: legal status and reclassification of medicines.www.mhra.gov.uk/home/ idcplg?IdcService=SS_ GET-PAGE&nodeId=107 (accessed February 1, 2006).
44. Non-prescription drugs: value of a pharmacist controlled class has yet to be demonstrated. Washington DC: United States General Accounting Office; 1995.
45. Deussen AR, Taylor A, Wilson D, Hiller JE. Does cost affect access to non-prescription pharmaceuticals? Aust N Z J Public Health 2001;25:572-3.
46. Benrimoj SI, Gilbert AL. National standards of practice for the provision of pharmacist only and pharmacy medicines in community pharmacy. Sydney: University of Sydney, University of South Australia; 2002.
47. Ryan M, Yule B. Switching drugs from prescription only to over-the-counter availability: economic benefits in the United Kingdom. Health Policy 1990;16:233-9.
48. Temin P. Costs and benefits in switching from Rx to OTC. J Health Econ 1983;2:187-205.
49. Second National Report on Patient Safety: Improving Medication Safety. Canberra: Australian Council for Safety and Quality in Health Care; 2002.
50. Galbally R. National competition review of drugs, poisons and controlled substances legislation. Woden ACT: Commonwealth of Australia; 2000.